Aug 24, 2010, 03.37 PM | Source: CNBC-TV18
Drug major Ranbaxy is likely to offer payment of one time penalty to US Food and Drug Administration (FDA), reports CNBC-TV18 quoting sources.
Facing the ban, Ranbaxy has been unable to export generic drug from Paonta Sahib and Deewas since September 2008.
It is learnt that Ranbaxy management is keen to settle with US FDA and offer to pay the penalty as one of the options. It is not known what the one time penalty will amount to.
However even if US FDA gives a nod to the penalty offer, its officials inspection of Ranbaxy’s plants is not ruled out. So the first inspection will be in Dewas because the issue is less complicated there.
Ranbaxy management has not denied to the story but only refused a comment calling it a market speculation.
Also watch the accompanying video.
AP, US govt ink pact to develop Visakhapatnam as 'Smart City'
State Principal Secretary (Municipal Administratio
Lupin confident of growth in US going ahead
"I now the first half of this year has been challe
Facebook India Head Kirthiga Reddy to relocate to US
China isn't the real worry, US economy is, says StanChart
Federal Reserve's next move would be a rate cut go
Sun Pharma to ask FDA in Q1 FY17 for Halol re-inspection
US crude jumps 4% from 12-year lows but outlook still bleak
US crude prices bounced away from 12-year lows ear
Sinha's extension as chief key to tackle global volatility: Srcs
Sources have also informerd that ex- Foward Market
Petronet LNG to renegotiate crude price in ExxonMobil deal: Srcs